Compare Stocks: VRCA, VNDA, LFCR, and BIOA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOA BioAge Labs	$5.47 +9.6%	$7.87	$4.81 ▼ $25.95	$251.06M	1.08	718,320 shs	1.11 million shs
LFCR Lifecore Biomedical	$6.44	$5.26	$3.63 ▼ $8.98	$243.75M	0.98	277,811 shs	441,610 shs
VNDA Vanda Pharmaceuticals	$3.99 +1.3%	$4.91	$3.88 ▼ $9.94	$241.24M	0.69	1.49 million shs	1.86 million shs
VRCA Verrica Pharmaceuticals	$3.47 +1.5%	$4.52	$3.28 ▼ $9.82	$59.61M	1.6	88,164 shs	27,985 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOA BioAge Labs	-2.16%	0.00%	-29.22%	-77.24%	-34.34%
LFCR Lifecore Biomedical	+0.63%	+0.78%	+53.33%	+46.70%	-5.01%
VNDA Vanda Pharmaceuticals	-1.75%	-3.67%	-21.98%	-23.64%	-28.36%
VRCA Verrica Pharmaceuticals	-3.12%	-0.58%	-21.74%	-36.67%	-11.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOA BioAge Labs	$5.47 +9.6%	$7.87	$4.81 ▼ $25.95	$251.06M	1.08	718,320 shs	1.11 million shs
LFCR Lifecore Biomedical	$6.44	$5.26	$3.63 ▼ $8.98	$243.75M	0.98	277,811 shs	441,610 shs
VNDA Vanda Pharmaceuticals	$3.99 +1.3%	$4.91	$3.88 ▼ $9.94	$241.24M	0.69	1.49 million shs	1.86 million shs
VRCA Verrica Pharmaceuticals	$3.47 +1.5%	$4.52	$3.28 ▼ $9.82	$59.61M	1.6	88,164 shs	27,985 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOA BioAge Labs	-2.16%	0.00%	-29.22%	-77.24%	-34.34%
LFCR Lifecore Biomedical	+0.63%	+0.78%	+53.33%	+46.70%	-5.01%
VNDA Vanda Pharmaceuticals	-1.75%	-3.67%	-21.98%	-23.64%	-28.36%
VRCA Verrica Pharmaceuticals	-3.12%	-0.58%	-21.74%	-36.67%	-11.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIOA BioAge Labs	2.63	Moderate Buy	$33.00	503.29% Upside
LFCR Lifecore Biomedical	1.80	Reduce	$6.50	0.93% Upside
VNDA Vanda Pharmaceuticals	2.44	Hold	$13.08	227.90% Upside
VRCA Verrica Pharmaceuticals	2.40	Hold	$12.67	265.03% Upside

Current Analyst Ratings Breakdown

Latest VRCA, VNDA, LFCR, and BIOA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/26/2026	BIOA BioAge Labs	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/16/2026	LFCR Lifecore Biomedical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/15/2026	VNDA Vanda Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/13/2026	VRCA Verrica Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/11/2026	BIOA BioAge Labs	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$8.00
10/11/2026	BIOA BioAge Labs	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/8/2026	BIOA BioAge Labs	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/6/2026	VNDA Vanda Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/5/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$20.00
10/2/2026	LFCR Lifecore Biomedical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/29/2026	LFCR Lifecore Biomedical	Barrington Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Hold

(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIOA BioAge Labs	$10.36M	24.24	N/A	N/A	$7.59 per share	0.72
LFCR Lifecore Biomedical	$128.87M	1.89	N/A	N/A	$0.42 per share	15.33
VNDA Vanda Pharmaceuticals	$216.10M	1.12	N/A	N/A	$5.54 per share	0.72
VRCA Verrica Pharmaceuticals	$30.32M	1.97	N/A	N/A	$1.55 per share	2.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIOA BioAge Labs	-$80.61M	-$2.38	N/A	N/A	N/A	-912.26%	-28.99%	-27.09%	N/A
LFCR Lifecore Biomedical	N/A	-$1.07	N/A	N/A	N/A	-29.93%	N/A	-16.16%	11/3/2026 (Estimated)
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	10/28/2026 (Estimated)
VRCA Verrica Pharmaceuticals	-$17.89M	-$1.67	N/A	N/A	N/A	-102.84%	-407.11%	-70.17%	11/13/2026 (Estimated)

Latest VRCA, VNDA, LFCR, and BIOA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	VRCA Verrica Pharmaceuticals	-$0.45	N/A	N/A	N/A	$6.20 million	N/A
11/3/2026	Q3 2026	LFCR Lifecore Biomedical	-$0.2975	N/A	N/A	N/A	$25.57 million	N/A
10/28/2026	Q3 2026	VNDA Vanda Pharmaceuticals	-$0.72	N/A	N/A	N/A	$69.20 million	N/A
8/5/2026	Q2 2026	BIOA BioAge Labs	-$0.65	-$0.58	+$0.07	-$0.58	N/A	$2.45 million
8/5/2026	Q2 2026	LFCR Lifecore Biomedical	-$0.19	-$0.19	N/A	-$0.19	$34.18 million	$34.17 million
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIOA BioAge Labs	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIOA BioAge Labs	N/A	17.19	17.19
LFCR Lifecore Biomedical	N/A	3.87	2.69
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60
VRCA Verrica Pharmaceuticals	0.18	1.45	1.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIOA BioAge Labs	N/A
LFCR Lifecore Biomedical	83.36%
VNDA Vanda Pharmaceuticals	88.14%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
BIOA BioAge Labs	17.55%
LFCR Lifecore Biomedical	32.68%
VNDA Vanda Pharmaceuticals	10.70%
VRCA Verrica Pharmaceuticals	52.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIOA BioAge Labs	62	45.90 million	37.84 million	Optionable
LFCR Lifecore Biomedical	382	37.85 million	25.48 million	Optionable
VNDA Vanda Pharmaceuticals	533	60.46 million	53.99 million	Optionable
VRCA Verrica Pharmaceuticals	76	17.18 million	8.09 million	Optionable

VRCA, VNDA, LFCR, and BIOA Headlines

Recent News About These Companies

Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility

October 22, 2026 | globenewswire.com

Lake Street sets USD 9.00 target for Verrica Pharmaceuticals stock

October 18, 2026 | ad-hoc-news.deA

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Has Average Target Price of $12.67

October 9, 2026 | marketbeat.com

Lake Street Keeps Their Buy Rating on Verrica Pharmaceuticals (VRCA)

October 6, 2026 | theglobeandmail.com

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

September 30, 2026 | globenewswire.com

Verrica Pharmaceuticals stock trades at USD 4.10

September 22, 2026 | ad-hoc-news.deA

Verrica Pharmaceuticals stock holds steady as investors watch latest clinical and earnings signals

September 21, 2026 | ad-hoc-news.deA

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

September 10, 2026 | globenewswire.com

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | globenewswire.com

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data ...

August 27, 2026 | finance.yahoo.com

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

August 27, 2026 | globenewswire.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Buys 4,200 Shares

August 19, 2026 | insidertrades.com

Verrica (VRCA) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 6, 2026 | manilatimes.netM

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

August 6, 2026 | finance.yahoo.com

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026 | globenewswire.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum ...

July 21, 2026 | markets.businessinsider.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

July 21, 2026 | globenewswire.com

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment ...

June 23, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA, VNDA, LFCR, and BIOA Company Descriptions

BioAge Labs NASDAQ:BIOA

$5.47 +0.48 (+9.62%)

Closing price 04:00 PM Eastern

Extended Trading

$5.69 +0.22 (+4.08%)

As of 05:33 PM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Lifecore Biomedical NASDAQ:LFCR

$6.44 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$6.44 -0.01 (-0.08%)

As of 04:10 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Vanda Pharmaceuticals NASDAQ:VNDA

$3.99 +0.05 (+1.27%)

Closing price 04:00 PM Eastern

Extended Trading

$3.96 -0.03 (-0.63%)

As of 05:20 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Verrica Pharmaceuticals NASDAQ:VRCA

$3.47 +0.05 (+1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$3.44 -0.03 (-0.86%)

As of 04:20 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRCA, VNDA, LFCR, and BIOA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRCA, VNDA, LFCR, and BIOA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRCA, VNDA, LFCR, and BIOA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA, VNDA, LFCR, and BIOA Company Descriptions

BioAge Labs NASDAQ:BIOA

Lifecore Biomedical NASDAQ:LFCR

Vanda Pharmaceuticals NASDAQ:VNDA

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRCA, VNDA, LFCR, and BIOA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRCA, VNDA, LFCR, and BIOA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRCA, VNDA, LFCR, and BIOA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA, VNDA, LFCR, and BIOA Company Descriptions

BioAge Labs NASDAQ:BIOA

Lifecore Biomedical NASDAQ:LFCR

Vanda Pharmaceuticals NASDAQ:VNDA

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools